Determination of β2-microglobulin in biological samples using an immunoenzymometric assay (chemiluminescence detection) or an immunoturbidimetric assay: Comparison with a radioimmunoassay

Clinical Laboratory

Volumn 50, Issue 11-12, 2004, Pages 675-683

  Terrier, N ^a   Bonardet, A ^a   Descomps, B ^a   Cristol, J P ^a   Dupuy, A M ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

2M; 2 microglobulin; Biological fluids; Immunochemiluminescence; Immunoturbidimetry; RIA

Indexed keywords

BETA 2 MICROGLOBULIN; HEMODIALYSIS FLUID; MICROSPHERE;

ANALYTIC METHOD; ARTICLE; BIOLOGICAL MONITORING; BLOOD SAMPLING; BODY FLUID; CALIBRATION; CHEMOLUMINESCENCE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; DIALYSATE; ENZYME IMMUNOASSAY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOASSAY; IMMUNOTURBIDIMETRY; INTERMETHOD COMPARISON; KIDNEY DISEASE; KIDNEY FAILURE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MYELOMA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RADIOIMMUNOASSAY; REFERENCE VALUE; RELIABILITY; URINALYSIS; BLOOD; CHEMISTRY; COMPARATIVE STUDY; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; IMMUNOPRECIPITATION; INSTRUMENTATION; METHODOLOGY; PHOTOMETRY; REPRODUCIBILITY; STATISTICAL MODEL; URINE;

BETA 2-MICROGLOBULIN; BODY FLUIDS; CHEMILUMINESCENT MEASUREMENTS; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; HEMODIALYSIS SOLUTIONS; HUMANS; IMMUNOASSAY; IMMUNOPRECIPITATION; LINEAR MODELS; MALE; MICROSPHERES; NEPHELOMETRY AND TURBIDIMETRY; RADIOIMMUNOSORBENT TEST; REPRODUCIBILITY OF RESULTS;

EID: 9244260144     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Barlogie B. High-dose therapy and innovative approaches to treatment of multiple myeloma. Semin Hematol 2001; 38 (2 Suppl 3):21-7.
2. Bataille R, Grenier J. Role of the assay of serum beta 2 microglobulin in the clinical evaluation of myeloma. Presse Med 1986 11 ;15(34):1723-5.
3. Bergoin C, Lamblin C, Wallaert B. Biological manifestations of sarcoidosis. Ann Med Interne (Paris) 2001; 152(1):34-8.
4. Bethea M, Forman DT. Beta 2-microglobulin: its significance and clinical usefulness. Ann Clin Lab Sci. 1990 ; 20(3):163-8.
5. Bhalla RB, Safai B, Pahwa S, Schwartz MK. β2-microglobulin as a prognostic marker for development of AIDS. Clin Chem 1985 ;31:1411-1412.
6. Bianchi C, Donadio C, Tramonti G, Consani C, Lorusso P, Rossi G. Reappraisal of serum beta2-microglobulin as marker of GFR. Ren Fail 2001 ;23(3-4):419-29.
7. Canaud B, Bosc JY, Leray H, Stec F, Argiles A, Leblanc M, Mion C. On-line haemodiafiltration: state of the art. Nephrol Dial Transplant 1998;13 Suppl 5:3-11
8. Canaud Garred LJ, Rittau M, McCready W, Canaud B. Urea kinetic modelling by partial dialysate collection. Int J Artif Organs 1989;12(2):96-102.
9. Davey PG, Goslin P. β-2 microglobulin instability in pathological urine. Clin Chem 1982; 28 :1330-1333.
10. Dommergues M, Muller F, Ngo S, Hohlfeld P, Oury JF, Bidat L, Mahieu-Caputo D, Sagot P, Body G, Favre R, Dumez Y. Fetal serum beta2-microglobulin predicts postnatal renal function in bilateral uropathies. Kidney Int 2000; 58(1):312-6.
11. Evrin PE, Peterson PA, Wide L, Berggard. Radioimmunoassay of beta2 -microglobulin in human biological fluids. Scand J Clin Lab Invest 1971 Dec;28(4):439-43.
12. Floege J, Ketteler M. Beta2-microglobulin-derived amyloidosis: an update. Kidney Int Suppl 2001;78:S164-71.
13. Garcia-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A,et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001 ;115(3):575-82.
14. Glikmanas G, Hamida F, Rainteau D, Ferrière F, Bonardet A, Jardel C, Meillet D, Thuillier F. Bêta 2-microglobuline: é tude comparative et transférabilité des résultats obtenus à partir de différents analyseurs. Immunoanal Biol Spéc 1997;2:29-35.
15. Gussow D, Rein R, Ginjaar I, Hochstenbach F, Seemann G, Kottman A, Ploegh HL. The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol 1987;139(9):3132-8.
16. Haferlach T, Loffler H. Prognostic factors in multiple myeloma: practicability for clinical practice and future perspectives. Leukemia 1997; 11 Suppl 5: S5-9
17. Hou FF, Owen WF Jr. Beta 2-microglobulin amyloidosis: role of monocytes/macrophages. Curr Opin Nephrol Hypertens 2002; 11(4): 417-21.
18. Le Bricon T. Identification et dosage des protéines urinaires au laboratoire d'analyses. Ann Biol Cli 2002; 60:525-40.
19. Lievens MM, Woestyn S, De Nayer P, Collet-Cassart D. Measurement of beta 2-microglobulin in serum by particle-enhanced nephelemetric immunoasay. Eur J Clin Chem Clin Biochem 1991; 29(6):401-4.
20. Locatelli F, Di Filippo S, Manzoni C. Removal of small and middle molecules by convective techniques. Nephrol Dial Transplant 2000; 15 Suppl 2:37-44.
21. Lutz CT, Cornell SH, Goeken JA. Establishment of a reference interval for beta-microglobulin in cerebrospinal fluid with use of two commercial assays. Clin Chem 1991; 37:104-107.
22. Miyata T., Jadoul M., Kurokawa K., van Ypersele de Strihou C. β-2 microglobulin in renal diseases. J Am Soc Nephrol, 1998; 9:1723-1735.
23. Newman DJ, Kassai M, Craig AR, Gorman EG, Price CP. Validation of a particle enhanced immunoturbidimetric assay for serum beta 2-microglobulin on the Dade Aca. Eur J Clin Chem Clin Biochem 1996;34(10):861-5
24. Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000; 95(2):359-67.
25. Rajkumar SV, Greipp PR. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am 1999; 13(6):1295-314.
26. Revillard JP, Vincent C. Structure and metabolism of β2-microglobulin. Contr Nephrol 1988; 62: 44-53.
27. Schardijn GHC, Statius Van Eps L.W. β2-microglobulin: Its significance in the evaluation of renal function. Kidney Int 1987; 32:635-641.
28. Steinhoff J, Feddersen A, Preuss R, Wood WG, Fricke L, Hoyer J, Sack K. Quantitative protein determination in urine: diagnostic value in renal transplant patients. Transplant Proc. 1992 Feb; 24(1): 362-5.
29. Solheim JC. Class I MHC molecules: assembly and antigen presentation. Immunol Rev 1999;172:11-9.
30. Strathdee SA, O'Shaughnessy MV, Montaner JS, Schechter MT. A decade of research on the natural history of HIV infection: Part 1. Markers. Clin Invest Med 1996; 19(2):111-20.
31. Uchanska-Ziegler B, Ziegler A. Ankylosing spondylitis: a beta2m-deposition disease? Trends Immunol 2003; 24(2):73-6.
32. Vassault A, Grafmeyer D, Naudin C, Dumont G, Bailly M, Henny J, Gerhardt MF, Georges P et les membres de la commission " Validation de techniques" de la SFBC. Protocole de validation de techniques. Ann Biol Clin 1986; 44: 686-745.
33. Vieldma JA, Pacheo, Albaladejo MD. Determination of Beta 2-Microglobulin in serum by a microparticle-enhanced nephelemetric immunoassay. Clin Chem 1992; 38(12):2462-2468.